All In Biotech

Drug Trial Radar · NCT07592689

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Major Depressive Disorder - Ascend

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

165

Planned (sponsor's estimate)

Start

May 10, 2026

Primary completion

Sep 2027

Study completion Jun 2028

Sponsor

Lead sponsor
Definium Therapeutics US, Inc.Industry
Sponsor type
Industry
First posted
May 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend

Conditions

  • Major Depressive Disorder

Interventions

  • PlaceboOther

    A substance that is designed to have no therapeutic value

  • DT120Drug

    A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6Time frame: Baseline to Week 6

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Preferred Research Partners, Inc.

    Little Rock, Arkansas · Recruiting

  • ATP Clinical Research Orange County

    Orange, California · Recruiting

  • Kadima Neuropsychiatry Institute

    San Diego, California · Recruiting

  • Psychedelic Science Institute

    Santa Monica, California · Recruiting

  • Mountain View Clinical Research, Inc

    Denver, Colorado · Recruiting

  • Clinical Neuroscience Solutions, LLC (Jacksonville)

    Jacksonville, Florida · Recruiting

  • K2 Medical Research (Maitland)

    Maitland, Florida · Recruiting

  • Clinical Neuroscience Solutions, LLC (Orlando)

    Orlando, Florida · Recruiting

  • K2 Medical Research (Tampa)

    Tampa, Florida · Recruiting

  • CenExel - Atlanta Center for Medical Research

    Atlanta, Georgia · Recruiting

  • CenExel - iResearch Atlanta

    Decatur, Georgia · Recruiting

  • CenExel - iResearch Savannah

    Savannah, Georgia · Recruiting

  • Uptown Research Institute

    Chicago, Illinois · Recruiting

  • Adams Clinical Boston

    Boston, Massachusetts · Active not recruiting

  • Adams Clinical Watertown

    Boston, Massachusetts · Recruiting

  • Vitalix Clinical

    Worcester, Massachusetts · Recruiting

  • Arch Clinical Trials, LLC

    St Louis, Missouri · Recruiting

  • Redbird Research

    Las Vegas, Nevada · Recruiting

  • Adams Clinical Harlem

    New York, New York · Active not recruiting

  • Adams Clinical Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Coastal Carolina Research

    North Charleston, South Carolina · Recruiting

  • Austin Clinical Trial Partners

    Austin, Texas · Recruiting

  • Cedar Clinical Research

    Draper, Utah · Recruiting

  • Inner Space Research

    Orem, Utah · Recruiting

  • Memory Clinic Inc.

    Bennington, Vermont · Recruiting

  • Seattle Neuropsychiatric Treatment Center

    Seattle, Washington · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.